India imposes anti-dumping duty on certain APIs from China

It was not so very long ago that Indian drugmakers were facing headwinds due to the spike in prices of active pharmaceutical ingredients (APIs) and intermediates being imported from China. From being dependent on China for APIs in the past, India has now swung to the opposite end of the spectrum and is imposing anti-dumping duties on several APIs and key starting materials that come from China, reports The Pharma Letter’s India correspondent.

For example, ofloxacin, a treatment for certain infections imported from China, is now subject to an anti-dumping duty by India's commerce ministry for a period of five years in an effort to protect the domestic industry against the cheap imports from the Asian neighbor.

The commerce ministry has also recommended the continuation of anti-dumping duties on some semi synthetic antibiotics imported from China, including amoxicillin trihydrate.